Previous studies have found that PP2A can inhibit the MYC gene and the AKT, KRAS, and NF-κB proteins [15–18], as well as other oncogenes and tumor signaling pathways, thereby exerting a tumor suppressor effect. The gene discussed is KRAS; the disease is neoplasm.